REGN5381/REGN9035
/ Regeneron
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 15, 2024
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants
(clinicaltrials.gov)
- P1 | N=93 | Completed | Sponsor: Regeneron Pharmaceuticals | Active, not recruiting ➔ Completed
Trial completion
December 11, 2023
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants
(clinicaltrials.gov)
- P1 | N=93 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting
Enrollment closed
September 05, 2023
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants
(clinicaltrials.gov)
- P1 | N=107 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Suspended ➔ Recruiting | Trial completion date: Jan 2024 ➔ Jul 2024 | Trial primary completion date: Jan 2024 ➔ Jul 2024
Enrollment open • Trial completion date • Trial primary completion date
May 06, 2023
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants
(clinicaltrials.gov)
- P1 | N=107 | Suspended | Sponsor: Regeneron Pharmaceuticals | Trial completion date: Oct 2023 ➔ Jan 2024 | Recruiting ➔ Suspended | Trial primary completion date: Oct 2023 ➔ Jan 2024
Trial completion date • Trial primary completion date • Trial suspension
1 to 4
Of
4
Go to page
1